Search

Supplemental material, sj-pdf-7-cep-10.1177_03331024211068065 for NCOR2 is a novel candidate gene for migraine-epilepsy phenotype by Marjo Eveliina Nuottamo, Paavo H��pp��l��, Ville Artto, Heidi Hautakangas, Matti Pirinen, Tero Hiekkalinna, Pekka Ellonen, Maija Lepist��, Eija H��m��l��inen, International Headache Genetics Consortium (IHGC), FinnGenConsortiumAuli Siren, Anna-Elina Lehesjoki, Mikko Kallela, Aarno Palotie, Mari Anneli Kaunisto and Maija Wessman in Cephalalgia

Supplemental material, sj-pdf-2-cep-10.1177_03331024211068065 for NCOR2 is a novel candidate gene for migraine-epilepsy phenotype by Marjo Eveliina Nuottamo, Paavo H��pp��l��, Ville Artto, Heidi Hautakangas, Matti Pirinen, Tero Hiekkalinna, Pekka Ellonen, Maija Lepist��, Eija H��m��l��inen, International Headache Genetics Consortium (IHGC), FinnGenConsortiumAuli Siren, Anna-Elina Lehesjoki, Mikko Kallela, Aarno Palotie, Mari Anneli Kaunisto and Maija Wessman in Cephalalgia

Supplemental material, sj-pdf-1-cep-10.1177_03331024211068065 for NCOR2 is a novel candidate gene for migraine-epilepsy phenotype by Marjo Eveliina Nuottamo, Paavo H��pp��l��, Ville Artto, Heidi Hautakangas, Matti Pirinen, Tero Hiekkalinna, Pekka Ellonen, Maija Lepist��, Eija H��m��l��inen, International Headache Genetics Consortium (IHGC), FinnGenConsortiumAuli Siren, Anna-Elina Lehesjoki, Mikko Kallela, Aarno Palotie, Mari Anneli Kaunisto and Maija Wessman in Cephalalgia

Supplemental material, sj-pdf-3-cep-10.1177_03331024211068065 for NCOR2 is a novel candidate gene for migraine-epilepsy phenotype by Marjo Eveliina Nuottamo, Paavo H��pp��l��, Ville Artto, Heidi Hautakangas, Matti Pirinen, Tero Hiekkalinna, Pekka Ellonen, Maija Lepist��, Eija H��m��l��inen, International Headache Genetics Consortium (IHGC), FinnGenConsortiumAuli Siren, Anna-Elina Lehesjoki, Mikko Kallela, Aarno Palotie, Mari Anneli Kaunisto and Maija Wessman in Cephalalgia

Supplemental material, sj-pdf-7-cep-10.1177_03331024211068065 for NCOR2 is a novel candidate gene for migraine-epilepsy phenotype by Marjo Eveliina Nuottamo, Paavo H��pp��l��, Ville Artto, Heidi Hautakangas, Matti Pirinen, Tero Hiekkalinna, Pekka Ellonen, Maija Lepist��, Eija H��m��l��inen, International Headache Genetics Consortium (IHGC), FinnGenConsortiumAuli Siren, Anna-Elina Lehesjoki, Mikko Kallela, Aarno Palotie, Mari Anneli Kaunisto and Maija Wessman in Cephalalgia

Supplemental material, sj-pdf-5-cep-10.1177_03331024211068065 for NCOR2 is a novel candidate gene for migraine-epilepsy phenotype by Marjo Eveliina Nuottamo, Paavo H��pp��l��, Ville Artto, Heidi Hautakangas, Matti Pirinen, Tero Hiekkalinna, Pekka Ellonen, Maija Lepist��, Eija H��m��l��inen, International Headache Genetics Consortium (IHGC), FinnGenConsortiumAuli Siren, Anna-Elina Lehesjoki, Mikko Kallela, Aarno Palotie, Mari Anneli Kaunisto and Maija Wessman in Cephalalgia

Supplemental material, sj-pdf-6-cep-10.1177_03331024211068065 for NCOR2 is a novel candidate gene for migraine-epilepsy phenotype by Marjo Eveliina Nuottamo, Paavo H��pp��l��, Ville Artto, Heidi Hautakangas, Matti Pirinen, Tero Hiekkalinna, Pekka Ellonen, Maija Lepist��, Eija H��m��l��inen, International Headache Genetics Consortium (IHGC), FinnGenConsortiumAuli Siren, Anna-Elina Lehesjoki, Mikko Kallela, Aarno Palotie, Mari Anneli Kaunisto and Maija Wessman in Cephalalgia

Supplemental material, sj-pdf-6-cep-10.1177_03331024211068065 for NCOR2 is a novel candidate gene for migraine-epilepsy phenotype by Marjo Eveliina Nuottamo, Paavo H��pp��l��, Ville Artto, Heidi Hautakangas, Matti Pirinen, Tero Hiekkalinna, Pekka Ellonen, Maija Lepist��, Eija H��m��l��inen, International Headache Genetics Consortium (IHGC), FinnGenConsortiumAuli Siren, Anna-Elina Lehesjoki, Mikko Kallela, Aarno Palotie, Mari Anneli Kaunisto and Maija Wessman in Cephalalgia

Supplemental material, sj-pdf-3-cep-10.1177_03331024211068065 for NCOR2 is a novel candidate gene for migraine-epilepsy phenotype by Marjo Eveliina Nuottamo, Paavo H��pp��l��, Ville Artto, Heidi Hautakangas, Matti Pirinen, Tero Hiekkalinna, Pekka Ellonen, Maija Lepist��, Eija H��m��l��inen, International Headache Genetics Consortium (IHGC), FinnGenConsortiumAuli Siren, Anna-Elina Lehesjoki, Mikko Kallela, Aarno Palotie, Mari Anneli Kaunisto and Maija Wessman in Cephalalgia

Supplemental material, sj-pdf-2-cep-10.1177_03331024211068065 for NCOR2 is a novel candidate gene for migraine-epilepsy phenotype by Marjo Eveliina Nuottamo, Paavo H��pp��l��, Ville Artto, Heidi Hautakangas, Matti Pirinen, Tero Hiekkalinna, Pekka Ellonen, Maija Lepist��, Eija H��m��l��inen, International Headache Genetics Consortium (IHGC), FinnGenConsortiumAuli Siren, Anna-Elina Lehesjoki, Mikko Kallela, Aarno Palotie, Mari Anneli Kaunisto and Maija Wessman in Cephalalgia

Supplemental material, sj-pdf-1-cep-10.1177_03331024211045651 for Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families by Paavo Häppölä, Padhraig Gormley, Marjo E Nuottamo, Ville Artto, Marja-Liisa Sumelahti, Markku Nissilä, Petra Keski-Säntti, Matti Ilmavirta, Mari A Kaunisto, Eija I Hämäläinen, Samuli Ripatti, Matti Pirinen, Maija Wessman, Aarno Palotie, Mikko Kallela and International Headache Genetics Consortium (IHGC) in Cephalalgia

ObjectiveTo assess whether the polygenic risk score (PRS) for migraine is associated with acute and/or prophylactic migraine treatment response.MethodsWe interviewed 2,219 unrelated patients at the Danish Headache Center using a semistructured interview to diagnose migraine and assess acute and prophylactic drug response. All patients were genotyped. A PRS was calculated with the linkage disequilibrium pred algorithm using summary statistics from the most recent migraine genome-wide association study comprising ∼375,000 cases and controls. The PRS was scaled to a unit corresponding to a twofold increase in migraine risk, using 929 unrelated Danish controls as reference. The association of the PRS with treatment response was assessed by logistic regression, and the predictive power of the model by area under the curve using a case-control design with treatment response as outcome.ResultsA twofold increase in migraine risk associates with positive response to migraine-specific acute treatment (odds ratio [OR] = 1.25 [95% confidence interval (CI) = 1.05–1.49]). The association between migraine risk and migraine-specific acute treatment was replicated in an independent cohort consisting of 5,616 triptan users with prescription history (OR = 3.20 [95% CI = 1.26–8.14]). No association was found for acute treatment with non–migraine-specific weak analgesics and prophylactic treatment response.ConclusionsThe migraine PRS can significantly identify subgroups of patients with a higher-than-average likelihood of a positive response to triptans, which provides a first step toward genetics-based precision medicine in migraine.

Objective: To apply genetic analysis of genome-wide association data to study the extent and nature of a shared biological basis between migraine and coronary artery disease (CAD). Methods: Four separate methods for cross-phenotype genetic analysis were applied on data from 2 large-scale genome-wide association studies of migraine (19,981 cases, 56,667 controls) and CAD (21,076 cases, 63,014 controls). The first 2 methods quantified the extent of overlapping risk variants and assessed the load of CAD risk loci in migraineurs. Genomic regions of shared risk were then identified by analysis of covariance patterns between the 2 phenotypes and by querying known genome-wide significant loci. Results: We found a significant overlap of genetic risk loci for migraine and CAD. When stratified by migraine subtype, this was limited to migraine without aura, and the overlap was protective in that patients with migraine had a lower load of CAD risk alleles than controls. Genes indicated by 16 shared risk loci point to mechanisms with potential roles in migraine pathogenesis and CAD, including endothelial dysfunction (PHACTR1) and insulin homeostasis (GIP). Conclusions: The results suggest that shared biological processes contribute to risk of migraine and CAD, but surprisingly this commonality is restricted to migraine without aura and the impact is in opposite directions. Understanding the mechanisms underlying these processes and their opposite relationship to migraine and CAD may improve our understanding of both disorders. CA extern

Supplemental material, Supplementary figure 1 for The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families by Marjo Eveliina Hiekkala, Pietari Vuola, Ville Artto, Paavo Häppölä, Elisa Häppölä, Salli Vepsäläinen, Ester Cuenca-León, Dennis Lal, Padhraig Gormley, Eija Hämäläinen, Matti Ilmavirta, Markku Nissilä, Erkki Säkö, Marja-Liisa Sumelahti, Hanna Harno, Hannele Havanka, Petra Keski-Säntti, Markus Färkkilä, Aarno Palotie, Maija Wessman, Mari Anneli Kaunisto and Mikko Kallela in Cephalalgia

Supplemental material, Supplementary table 1 for The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families by Marjo Eveliina Hiekkala, Pietari Vuola, Ville Artto, Paavo Häppölä, Elisa Häppölä, Salli Vepsäläinen, Ester Cuenca-León, Dennis Lal, Padhraig Gormley, Eija Hämäläinen, Matti Ilmavirta, Markku Nissilä, Erkki Säkö, Marja-Liisa Sumelahti, Hanna Harno, Hannele Havanka, Petra Keski-Säntti, Markus Färkkilä, Aarno Palotie, Maija Wessman, Mari Anneli Kaunisto and Mikko Kallela in Cephalalgia

Supplemental material, Supplementary table 3 for The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families by Marjo Eveliina Hiekkala, Pietari Vuola, Ville Artto, Paavo Häppölä, Elisa Häppölä, Salli Vepsäläinen, Ester Cuenca-León, Dennis Lal, Padhraig Gormley, Eija Hämäläinen, Matti Ilmavirta, Markku Nissilä, Erkki Säkö, Marja-Liisa Sumelahti, Hanna Harno, Hannele Havanka, Petra Keski-Säntti, Markus Färkkilä, Aarno Palotie, Maija Wessman, Mari Anneli Kaunisto and Mikko Kallela in Cephalalgia

Supplemental material, Supplementary table 2 for The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families by Marjo Eveliina Hiekkala, Pietari Vuola, Ville Artto, Paavo Häppölä, Elisa Häppölä, Salli Vepsäläinen, Ester Cuenca-León, Dennis Lal, Padhraig Gormley, Eija Hämäläinen, Matti Ilmavirta, Markku Nissilä, Erkki Säkö, Marja-Liisa Sumelahti, Hanna Harno, Hannele Havanka, Petra Keski-Säntti, Markus Färkkilä, Aarno Palotie, Maija Wessman, Mari Anneli Kaunisto and Mikko Kallela in Cephalalgia

Supplemental material, Supplementary figure 2 for The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families by Marjo Eveliina Hiekkala, Pietari Vuola, Ville Artto, Paavo Häppölä, Elisa Häppölä, Salli Vepsäläinen, Ester Cuenca-León, Dennis Lal, Padhraig Gormley, Eija Hämäläinen, Matti Ilmavirta, Markku Nissilä, Erkki Säkö, Marja-Liisa Sumelahti, Hanna Harno, Hannele Havanka, Petra Keski-Säntti, Markus Färkkilä, Aarno Palotie, Maija Wessman, Mari Anneli Kaunisto and Mikko Kallela in Cephalalgia

Supplemental material, Supplementary table 1 for The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families by Marjo Eveliina Hiekkala, Pietari Vuola, Ville Artto, Paavo Häppölä, Elisa Häppölä, Salli Vepsäläinen, Ester Cuenca-León, Dennis Lal, Padhraig Gormley, Eija Hämäläinen, Matti Ilmavirta, Markku Nissilä, Erkki Säkö, Marja-Liisa Sumelahti, Hanna Harno, Hannele Havanka, Petra Keski-Säntti, Markus Färkkilä, Aarno Palotie, Maija Wessman, Mari Anneli Kaunisto and Mikko Kallela in Cephalalgia

Supplemental material, Supplementary figure 3 for The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families by Marjo Eveliina Hiekkala, Pietari Vuola, Ville Artto, Paavo Häppölä, Elisa Häppölä, Salli Vepsäläinen, Ester Cuenca-León, Dennis Lal, Padhraig Gormley, Eija Hämäläinen, Matti Ilmavirta, Markku Nissilä, Erkki Säkö, Marja-Liisa Sumelahti, Hanna Harno, Hannele Havanka, Petra Keski-Säntti, Markus Färkkilä, Aarno Palotie, Maija Wessman, Mari Anneli Kaunisto and Mikko Kallela in Cephalalgia

Supplemental material, Supplementary table 3 for The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families by Marjo Eveliina Hiekkala, Pietari Vuola, Ville Artto, Paavo Häppölä, Elisa Häppölä, Salli Vepsäläinen, Ester Cuenca-León, Dennis Lal, Padhraig Gormley, Eija Hämäläinen, Matti Ilmavirta, Markku Nissilä, Erkki Säkö, Marja-Liisa Sumelahti, Hanna Harno, Hannele Havanka, Petra Keski-Säntti, Markus Färkkilä, Aarno Palotie, Maija Wessman, Mari Anneli Kaunisto and Mikko Kallela in Cephalalgia

Supplemental material, Supplementary figure 1 for The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families by Marjo Eveliina Hiekkala, Pietari Vuola, Ville Artto, Paavo Häppölä, Elisa Häppölä, Salli Vepsäläinen, Ester Cuenca-León, Dennis Lal, Padhraig Gormley, Eija Hämäläinen, Matti Ilmavirta, Markku Nissilä, Erkki Säkö, Marja-Liisa Sumelahti, Hanna Harno, Hannele Havanka, Petra Keski-Säntti, Markus Färkkilä, Aarno Palotie, Maija Wessman, Mari Anneli Kaunisto and Mikko Kallela in Cephalalgia

Supplemental material, Supplementary figure 3 for The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families by Marjo Eveliina Hiekkala, Pietari Vuola, Ville Artto, Paavo Häppölä, Elisa Häppölä, Salli Vepsäläinen, Ester Cuenca-León, Dennis Lal, Padhraig Gormley, Eija Hämäläinen, Matti Ilmavirta, Markku Nissilä, Erkki Säkö, Marja-Liisa Sumelahti, Hanna Harno, Hannele Havanka, Petra Keski-Säntti, Markus Färkkilä, Aarno Palotie, Maija Wessman, Mari Anneli Kaunisto and Mikko Kallela in Cephalalgia

Supplemental material, Supplementary figure 2 for The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families by Marjo Eveliina Hiekkala, Pietari Vuola, Ville Artto, Paavo Häppölä, Elisa Häppölä, Salli Vepsäläinen, Ester Cuenca-León, Dennis Lal, Padhraig Gormley, Eija Hämäläinen, Matti Ilmavirta, Markku Nissilä, Erkki Säkö, Marja-Liisa Sumelahti, Hanna Harno, Hannele Havanka, Petra Keski-Säntti, Markus Färkkilä, Aarno Palotie, Maija Wessman, Mari Anneli Kaunisto and Mikko Kallela in Cephalalgia